Designation supports phase 3 launch in watch-and-wait patients in 2026
News
NIHR invests £157 million in research partnerships to transform healthcare
Applied Research Collaborations to drive innovation and tackle inequalities across England
Ultra-rapid insulin shows promise in phase 3 trial for type 1 diabetes
BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog
AbbVie unveils new data on solid tumour therapies
Phase 1 and phase 2 results highlight promise of ADCs for hard-to-treat cancers
Kainos secures NHS England contract to boost digital preventative healthcare
Three-year partnership to expand at-home health checks and vaccination access via NHS App
New treatment option for endometriosis approved in Scotland
Linzagolix with add-back Therapy accepted for use within NHS Scotland
Scotland approves new treatment option for multiple myeloma patients
Blenrep combination offers improved survival for those ineligible for lenalidomide
Orexa reports promising results in post-operative recovery trial
Dutch biotech’s ORE-001 shows strong potential to prevent ileus after major surgery
UK and US unite to fast-track medical innovation
New MHRA–FDA collaboration aims to boost patient access and AI safety
Herantis advances HER-096 after successful Phase 1b Parkinson’s trial
Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026
Experts call for urgent action to improve Alzheimer’s diagnosis across Europe
New survey reveals critical gaps in access to testing and timely care
Hikma and Celltrion deepen alliance to boost biosimilar access in MENA
Six new treatments aim to improve patient outcomes across key areas
Sheffield leads UK trial into stem cell treatment for severe scleroderma
UPSIDE study explores early transplant therapy for rare autoimmune disease
AC Immune’s Tau-targeting therapy shows promise in early Alzheimer’s trial
Early-stage study reveals strong immune response and safety profile for ACI-35.030
Xeltis prepares for commercial launch after strong aXess trial results
EU phase 3 data shows major gains in dialysis access performance
